leisure time -WSS

leisure time

author：knowledge 2025-10-01 17:35:20 - browse：9656

This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

There is now a drug on the U.S. market, approved this week, called Bkemv. I’m not kidding. I wish I were.

I’m flying to Chicago today for the ASCO meeting. I’ll be posting cancer-related dispatches all weekend, in case you need something to read on the beach.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： ARCH Venture Partners tops STAT's 2023 biotech VC rankings

leisure time

WSS

Doctors find melanoma drugs effective against rare brain cancer

Change Healthcare outage fallout shows need for new oversight

How Medicaid coverage policies for immigrants impact new moms

Group opposing PBM reform sets lobbying record

How to save health care price transparency rules

Male and female sex labels in research insufficient, scientists say

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

A public scorecard can help hold safety

In age of alternative facts, a scholarly course on calling out crap

Why hospitals are withdrawing from US News rankings

Alkermes shareholders re

How many hemophilia patients actually want gene therapy?

Hepatitis C has a cure — but many Americans still lack access to it

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Drug repurposing or repositioning? The language matters

How Medicaid coverage policies for immigrants impact new moms

hotspot

EPA limits use of carcinogenic gas for sterilizing medical devices

In early work, researchers turn to CRISPR to treat Alzheimer's

Biden tests positive for Covid

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

hotspot

leisure time

focus

focus